-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。目標株価を236ドルに据え置き、これは2027年の新たなEPS予想の13.8倍に相当します。これは、BIIBの過去5年間の予想PER平均である14.1倍を割り引いた水準です。買収したIPR&Dの影響を考慮し、2026年のEPS予想を16.14ドルから15.24ドルに下方修正しました。2027年のEPS予想は17.16ドルに据え置きます。BIIBは2026年を好調にスタートし、売上高は25億ドル、調整後EPSは3.57ドルとなりました。成長製品ポートフォリオが前年比12%増加したことから、長年の低迷を経て事業の安定化に成功したと見ています。当社の見解では、アナリスト向け説明会において、経営陣は、第2四半期に完了予定の56億ドル規模のアペリス買収を中心とした明確な戦略ビジョンを提示しました。この買収により、BIIBはSyfovreとEmpaveliという2つの商業資産を獲得し、成長企業へと変貌を遂げる可能性があります。当社は、アペリス買収によって、同社の後期開発段階のパイプラインが成熟する2028年までの収益ギャップを埋めることができると考えています。また、この買収を通じて、BIIBは腎臓病学の専門知識と確立されたインフラを獲得し、主要資産であるフェルザルタマブの発売を成功に導くことができるでしょう。
Related Articles
Mining & Metals
Bausch Health Q1 Adjusted Earnings, Revenue, Advance, Beating Estimates
Bausch Health (BHC.TO) up 3.6% in after-hours New York trade, after the company on Wednesday said its first-quarter adjusted earnings and revenue both rose, beating estimates.Adjusted net income, which excludes most one-time items, rose to US$296 million, or US$0.78 per share, from US$220 million, or US$0.59, in the prior-year period. Analysts polled by FactSet had expected US$0.67 per share.Consolidated revenue jumped 12% to US$2.52 billion, beating the US$2.4 billion FactSet forecast.Bausch Health maintained its fiscal 2026 revenue guidance of US$5.25 billion to US$5.4 billion and adjusted EBITDA of US$2.875 billion to US$2.95 billion, both excluding Bausch + Lomb."Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said chief executive Thomas Appio.Bausch Health shares were last seen up US$0.20, to US$5.79 in after-hours trade. They closed down $0.11 to $7.66 on the Toronto Stock Exchange.
$BHC$BHC.TO
Research
Research Alert: CFRA Raises Opinion On Shares Of Penske Automotive Group To Hold From Sell
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $25 to $170, based on a 2027 P/E of 11.8x, a premium to the stock's 10-year forward P/E of 9.8x. We lower our EPS estimates to $13.40 from $13.85 for 2026 and to $14.35 from $15.00 for 2027. However, we are raising our price target and our rating to Hold from Sell. This morning, PAG posted Q1 adjusted EPS of $3.05 vs. $3.59 (-15%), ahead of the $2.88 consensus. The beat was driven by a stronger-than-expected top line, as revenue fell 1.1% to $7.86B ($150M ahead of consensus) and gross margin contracted 10 bps to 16.5% (10 bps short of consensus). While we continue to view the stock's valuation as full and prefer other names in the auto dealership space, currency has provided a significant earnings tailwind for PAG given its significant international exposure, allowing it to exceed Street expectations. Additionally, the company continues to return cash to shareholders in the form of buybacks and dividends, helping support EPS amid demand-related headwinds.
$PAG
Mining & Metals
Earnings Flash (CS.TO) Capstone 2026 Production Guidance of 200,000-230,000 Tonnes Copper and C1 Cash Costs Guidance of US$2.45-$2.75 Per Payable Pound Unchanged
$CS.TO